Donald A. Brand

Donald A. Brand

Auto-generated profile, based on publicly available information

Donald A. Brand

NYU Long Island School of Medicine, 101 Mineola Boulevard, Suite 3-041, Mineola, NY, 11501, USA.

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
NKNadia B. Kunzier
Nadia B. Kunzier
WKWendy L. Kinzler
Wendy L. Kinzler
MCMartin R. Chavez
Martin R. Chavez
TATracy M. Adams
Tracy M. Adams
DBDonald A. Brand
Donald A. Brand
AVAnthony M. Vintzileos
Anthony M. Vintzileos

1 August 2019 in Endocrine Practice
Verified
Journal Article
Closed access
DBDonald A. Brand
Donald A. Brand
VPVirginia Peragallo-Dittko
Virginia Peragallo-Dittko
MFMelissa J. Fazzari
Melissa J. Fazzari
SIShahidul Islam
Shahidul Islam
AJAlan M. Jacobson
Alan M. Jacobson
MRMichael S. Radin
Michael S. Radin

1 March 2005 in Palliative and Supportive Care
Verified
Journal Article
Closed access
PDF file
JBJohn R. Brechtl
John R. Brechtl
PPPatricia A. Patrick
Patricia A. Patrick
PVPaul Visintainer
Paul Visintainer
DBDonald A. Brand
Donald A. Brand
Objectives: This study sought to identify potential predictive variables of death within 6 months in patients with advanced AIDS.Methods: Investigators enrolled a consecutive series of patients with advanced AIDS admitted to a skilled nursing facility in New York City over a 1-year period. Demographic, clinical, laboratory, and outcome data were abstracted from medical records using a standardized data collection instrument.Results: Of the 152 patients enrolled during the study period, 61 patients (40%) died within 6 months from date of admission. Serum albumin, percent deviation from ideal body weight, and number of comorbidities at the time of admission proved to be the best combination of predictors of death within 6 months.Significance of results: The decrease in AIDS mortality over the past decade, along with an increase in prevalence due to longer survival, has been attributed primarily to the successful use of highly active antiretroviral therapy (HAART). HAART regimens, however, can also produce both short-term adverse effects and long-term complications. The prognostic model developed by this study may be useful in guiding treatment decisions in patients with advanced AIDS for whom a more palliative care plan may be sought.

5 August 2019 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
DBDonald A. Brand
Donald A. Brand
During the initial consultation with a patient to communicate a diagnosis of late-stage cancer, the oncologist may refrain from giving survival statistics, redirecting the conversation from the bad news (incurability) to the practical aspects of the patient’s care (treatments, timetables, appointments, and testing to monitor response to treatment). Whether conscious or unconscious, this diversion helps cushion the impact of the disturbing news. This paper shows that clinicians’ gingerly handling of harsh facts when they talk with patients also applies to health educators and researchers when they write about late-stage cancer. As a result, these cancer patients typically lack an understanding of their poor prognosis and the limited effectiveness of most available treatments, possibly compromising their ability to make informed choices. To remedy this problem, I describe an approach to straight talk about late-stage cancer that can give a patient realistic hopes instead of false hopes that are apt to betray later on. I also propose an enhanced method of displaying and interpreting comparative efficacy data that can facilitate understanding and serve as a basis for shared decision making.

1 March 1990 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
DBDonald A. Brand
Donald A. Brand
MKMartin H. Krag
Martin H. Krag
MHMichael R. Hausman
Michael R. Hausman
KTKathryn F. Trainor
Kathryn F. Trainor
EAEdward Akelman
Edward Akelman
WSWayne O. Southwick
Wayne O. Southwick

23 April 2019 in Journal of Human Lactation
Verified
Journal Article
Closed access
PDF file
FLFarrah B. Lazare
Farrah B. Lazare
DBDonald A. Brand
Donald A. Brand
MFMelissa J. Fazzari
Melissa J. Fazzari
ANAsif Noor
Asif Noor
FDFredric Daum
Fredric Daum
Background: When an exclusively breastfed infant develops hematochezia, the pediatrician may recommend elimination of dairy and soy products from a mother’s diet, but there is limited scientific evidence to indicate that altering the maternal diet will lead to resolution of the problem. Research aim: To estimate the likelihood that maternal dairy and soy avoidance will resolve rectal bleeding in an exclusively breastfed infant. Methods: This was a prospective, longitudinal, one-group pre/post study involving mothers of exclusively breastfed infants at least 2 weeks but less than 6 months of age with a positive stool guaiac test in the absence of an intestinal lesion or other explanation for the blood. Participants agreed to follow a dairy and soy elimination/rechallenge protocol, maintain a food diary, and have their infant re-tested at 3-week intervals to determine the outcome of the dietary changes. One participant was lost to follow-up, leaving a final sample size of N = 19. Results: All infants continued to test positive for blood in the stool after their mothers eliminated foods containing dairy or soy. Therefore, 0% (0/19) of infants responded to their mother’s restricted diet, 95% confidence interval (one-sided [0%, 15%]). Conclusion: Given these results, we must call into question the rationale for advising breastfeeding mothers to eliminate dairy and soy from their diet in response to their infant’s unexplained rectal bleeding.